Pharmaceuticals
* Please select month and year together
May 9, 2025 –
May & Baker Nigeria Plc has declared a dividend. The following are the details related to the dividend: Ex-Dividend date 21/05/2025 Record date 20/05/2025 Payment date 05/06/2025 Dividend amount per share 0.4 NGN
Corporate announcement, Dividends | Nigeria
Discover the key insights from MeCure Industries Plc’s Q1 2025 Interim Financial Statement, highlighting a 65% revenue increase to ₦13.29 billion, total assets growth to ₦59.62 billion, and management’s strategic outlook amidst current financial challenges.
Document type: Interim Reports
Published: May 5, 2025
Year: 2025
Period: Q1
Pharmaceuticals | Nigeria
Discover Neimeth International Pharmaceuticals Plc’s interim financial statement summary as of 31 March 2025, highlighting asset growth, revenue increase, and profitability. Explore key insights into equity changes, cash flow performance, and associated risks.
Document type: Interim Reports
Published: May 5, 2025
Year: 2025
Period: Q1
Pharmaceuticals | Nigeria
Discover Neimeth International Pharmaceuticals PLC’s 2024 Annual Report, highlighting a remarkable 103% revenue growth to N4.5 billion despite a net loss of N885.3 million. Explore operational improvements, strategic investments, and future outlooks in financial performance and sustainability initiatives.
Document type: Annual Reports
Published: Apr 28, 2025
Year: 2024
Period:
Pharmaceuticals | Nigeria
Discover May & Baker Nig Plc’s Q1 2025 financial performance, showcasing significant revenue growth, increased assets, and strategic investments for future expansion.
Document type: Interim Reports
Published: May 5, 2025
Year: 2025
Period: Q1
Pharmaceuticals | Nigeria
Discover JULI PLC’s Interim Financial Statement for Q1 2025, highlighting a notable loss and changes in assets, liabilities, and equity. Explore key revenue insights, cash flow dynamics, and potential risks affecting the company’s financial outlook.
Document type: Interim Reports
Published: May 5, 2025
Year: 2025
Period: Q1
Pharmaceuticals | Nigeria
Discover the 2024 Annual Report summary for Intravenous Infusions PLC (IIPLC), detailing financial performance, operational highlights, strategic initiatives, and risk management insights. Despite challenges, IIPLC is poised for future growth with the launch of its subsidiary FLEXFLAC LTD.
Document type: Annual Reports
Published: Apr 29, 2025
Year: 2024
Period:
Pharmaceuticals | Ghana
Discover the key highlights from Africure Pharmaceuticals Ltd’s Annual Report 2023-24, including financial performance, operational challenges, strategic initiatives, and sustainable practices. Learn how the company navigated setbacks while focusing on growth in Sub-Saharan Africa’s generic market.
Document type: Annual Reports
Published: Jun 20, 2024
Year: 2024
Period:
Pharmaceuticals | Mauritius
Africure Pharmaceuticals Ltd (AFRP.mu) listed on the Stock Exchange of Mauritius under the Pharmaceuticals sector has released its 2025 interim results for the third quarter.
Document type: Interim Reports
Published: Mar 24, 2025
Year: 2025
Period: Q3
Pharmaceuticals | Mauritius
Juli Plc (JULI.ng) listed on the Nigerian Stock Exchange under the Pharmaceuticals sector has released its 2024 abridged results.
Document type: Abridged Reports
Published: Mar 24, 2025
Year: 2024
Period:
Pharmaceuticals | Nigeria
Intravenous Infusions Limited (IIL.gh) listed on the Ghana Stock Exchange under the Pharmaceuticals sector has released its 2024 abridged results.
Document type: Abridged Reports
Published: Mar 19, 2025
Year: 2024
Period:
Pharmaceuticals | Ghana
MeCure Industries Plc: Leading Nigerian pharmaceutical manufacturer, offering high-quality medicines and supplements with a strong market presence.
Pharmaceuticals | Nigeria
THE INVESTOR MAILING LIST
The investor mailing list (IML) is an investor relations newsletter focused on African stock markets. The IML has all the essential share trading updates, financial documents, news and corporate announcements. The newsletter currently covers 11 African stock markets and is free.